Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing of Sipuleucel-T and ADT in Non-metastatic Prostate Cancer
NCT01431391Phase 2Completed
- Sponsor
- Dendreon
- Start
- Sep 2011
- Primary completion
- Dec 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sipuleucel-T in prostate cancer (PCa) (2 arms), sponsored by Dendreon. Primary endpoint: Immune Response at Month 24 as Evaluated by IFN-γ ELISPOT Specific for PA2024. Started Sep 2011; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01431391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431391.